Advanced glycation end product precursors impair epidermal growth factor receptor signalin by Portero Otín, Manuel et al.
Advanced Glycation End Product Precursors Impair
Epidermal Growth Factor Receptor Signaling
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Robert Salvayre,2 and Anne Ne`gre-Salvayre2
Formation of advanced glycation end products (AGEs)
is considered a potential link between hyperglycemia
and chronic diabetic complications, including distur-
bances in cell signaling. It was hypothesized that AGEs
alter cell signaling by interfering with growth factor
receptors. Therefore, we studied the effects of two AGE
precursors, glyoxal (GO) and methylglyoxal (MGO), on
the epidermal growth factor receptor (EGFR) signaling
pathway in cultured cells. Both compounds prevented
tyrosine autophosphorylation induced by epidermal
growth factor (EGF) in a time- and dose-dependent
manner as well as phospholipase C1 recruitment and
subsequent activation of extracellular signal-regulated
kinases. AGE precursors inhibit EGF-induced EGFR
autophosphorylation and tyrosine kinase activity in cell
membranes and in EGFR immunoprecipitates. In addi-
tion, AGE precursors strongly inhibited cellular phos-
photyrosine phosphatase activities and residual EGFR
dephosphorylation. AGE precursors induced the forma-
tion of EGFR cross-links, as shown by the cross-reactiv-
ity of modified EGFR with an anti-N(carboxymethyl)
lysine antibody, suggesting that altered EGFR signaling
was related to carbonyl-amine reactions on EGFR. Ami-
noguanidine, an inhibitor of AGE formation, partially
prevented the EGFR dysfunction induced by GO and
MGO. These data introduce a novel mechanism for
impaired cellular homeostasis in situations that lead to
increased production of these reactive aldehydes, such
as diabetes. Diabetes 51:1535–1542, 2002
The Maillard reaction comprises the nonenzy-matic reaction of reducing sugars with mole-cules containing an amino group, includingproteins, phospholipids, and DNA (1,2). After the
reversible formation of a Schiff’s base between the reduc-
ing sugar and free amino group, this reaction proceeds to
form advanced glycation end products (AGEs). Aldehydes
such as glyoxal (GO) and methylglyoxal (MGO) are also
able to induce AGE formation (3). GO and MGO can be
generated during glycation of proteins by glucose (3); dur-
ing lipid peroxidation (4); from metabolic processes, such
as base-catalyzed phosphate elimination of glyceraldehyde
3-phosphate and dihydroxyacetone phosphate; and also
during the metabolism of acetone and threonine (5).
During chronic complications of diabetes and aging, the
levels of AGEs derived from the reaction of GO and MGO
with proteins rise in plasma proteins, extracellular matrix,
and lens proteins (6–8). Modification of proteins through
derivatization by GO and MGO may induce interaction
with specific receptors, such as the RAGE and AGE-R family
(9), or directly alter protein functions. For instance, MGO
inhibits mitochondrial respiration, membrane ATPases
and glyceraldehyde-3-phosphate dehydrogenases (10), and
DNA and protein synthesis, thereby inducing growth ar-
rest and cell death (11).
Because altered response to growth factor may be
implicated in the pathogenesis of diabetic ulcers (12) and
vascular diseases associated with diabetes (13), we hy-
pothesized that GO and MGO may modify growth factor
receptors and alter the subsequent signaling. Our investi-
gations were mainly focused on the epidermal growth
factor receptor (EGFR) because high glucose concentra-
tions lead to abnormal epidermal growth factor (EGF)
signaling (14) and diabetes reduces EGFR autophosphor-
ylation (15–17).
The EGFR belongs to a large family of tyrosine kinase
receptors and is involved in the regulation of multiple
cellular processes, such as cell growth, motility, differen-
tiation, survival, and death. The EGFR is a 170-kDa trans-
membrane receptor tyrosine kinase that is shared by
several growth factors, including EGF, heparin-binding
EGF, transforming growth factor-, amphiregulin, neuro-
regulin, -cellulin, and epiregulin (18). Ligand binding
induces EGFR dimerization, stimulation of intrinsic ty-
rosine kinase, and autophosphorylation of its own tyrosine
residues. These residues are binding sites for SH2 domains
of enzymatic proteins, such as phospholipase C1 (PLC1),
phosphatidylinositol 3-kinase, phosphotyrosine phospha-
tase SHP2, ras-GTPase activating protein, and/or adaptors
such as Shc isoforms, Grb2, Grb7, and Nck, which mediate
downstream signaling (rev. in 18).
In the present study, we report that the AGE precursors
GO and MGO alter EGF-induced EGFR activation in
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cultured cells through a mechanism related to AGE for-
mation in EGFR.
RESEARCH DESIGN AND METHODS
Chemicals. RPMI-1640 containing 2 mmol/l Glutamax, Dulbecco’s modified
Eagle’s medium (DMEM), penicillin, streptomycin, and FCS were purchased
from Gibco (Cergy-Pontoise, France). [3H]succinimidyl propionate ([3H]SP),
horseradish peroxidase–conjugated sheep anti–mouse Ig, and the ECLr (en-
hanced chemiluminescence) system were obtained from Amersham Pharma-
cia Biotech (Buckinghamshire, U.K.). [-33P]ATP (5 Ci/mmol) was supplied by
ICN Biomedicals (Orsay, France). Anti-phosphotyrosine (4G10, mouse mono-
clonal) was purchased from UBI (Euromedex, Souffelweyersheim, France),
anti-EGFR (rabbit polyclonal) and anti–platelet-derived growth factor recep-
tor (PDGFR) were from Santa Cruz (Tebu, France), and horseradish peroxi-
dase–conjugated goat anti–rabbit and acrylamide bisacrylamide were from
Bio-Rad (Mu¨nchen, Germany). Polyvinylidene difluoride (PVDF) Immobilon-P
membranes came from Millipore (Bedford, MA) and human recombinant EGF
and platelet-derived growth factor (PDGF) from PeproTech (Tebu, France).
GO, MGO, and protein G-Sepharose were from Sigma (St. Louis, MO). Anti-
phosphorylated (activated) extracellularly regulated kinases (ERKs), and
anti–total ERK antibodies were supplied by Promega (Madison, WI). Rabbit
polyclonal anti-N(carboxymethyl)lysine (CML) antiserum was obtained as
previously described (19).
Cell culture, dicarbonyl treatments, and viability assessment. ECV304,
A431 cell lines, and smooth muscle cells were obtained from the American
Type Culture Collection (Rockville, MD). The EGFR-transformed fibroblast
cell line B82-K, overexpressing human EGFR, was generously donated by
Dr. M.J. Weber (Health Sciences Center, Department of Microbiology, Univer-
sity of Virginia, Charlottesville, VA) (20).
Under standard conditions, cells were grown in RPMI-1640 (ECV304) or in
DMEM (A431 and B82K) supplemented with 10% heat-inactivated FCS,
Glutamax, 100 units/ml penicillin, and 100 g/ml streptomycin, as previously
described (21). All passages were made at a split ratio of 1:3.
Cell viability was evaluated by using the 3-(4,5-dimethyl thiazol-2-yl)-2,5-
diphenyl tetrazolium bromide (MTT) test (21) and the trypan blue exclusion
test. Subconfluent cells were starved overnight in serum-free RPMI before
addition of GO or MGO at the times and concentrations indicated below.
EGFR was stimulated by adding 10 nmol/l EGF at 37°C for 15 min. EGF
pulse-chase experiments were performed as previously described (22).
Western blot and immunoprecipitation analyses. Cells were washed in
ice-cold PBS containing 20 mmol/l NaF, 20 mmol/l Na4P2O7, 1 mmol/l Na3VO4,
and 5 mmol/l EDTA. Cells were lysed with solubilizing buffer (50 mmol/l
HEPES [pH 7.4], 150 mmol/l NaCl, 1 mmol/l Na3VO4, 20 mmol/l NaF, 10 mmol/l
Na4P2O7, 2.5 mmol/l phenylmethylsulfonyl fluoride, 10 mol/l leupeptin, 10
g/ml aprotinin, 10% glycerol, 1% Triton X-100, and 0.5% sodium deoxy-
cholate) for 30 min on ice. Insoluble materials were removed by centrifugation
(15,000 rpm at 4°C for 15 min).
Cell proteins (50 g) or, when indicated, immunoprecipitated EGFR were
resolved by SDS-PAGE electrophoresis, transferred onto PVDF membranes
that were blocked with 1% BSA, probed with the appropriate primary
antibody, and revealed by a peroxidase-coupled secondary antibody and ECL
detection, as previously indicated (23). The detection of CML adducts was
performed using anti-CML antiserum as previously described (19). ERK
activation was investigated through Western blot experiments on cell homog-
enates using an anti-phosphorylated ERK (anti-pERK) antibody and an
anti-total ERK (anti-ERK) antibody.
In vitro EGFR autophosphorylation and tyrosine kinase activity. EGFR
autophosphorylation and tyrosine kinase activity were assayed on EGFR
immunoprecipitated from ECV304 cells or on plasma membranes isolated
from A431 cells (overexpressing EGFR), under the previously used conditions
(23). Briefly, after preincubation with GO or MGO, EGFR immunoprecipitates
or A431 plasma membranes (40 g/assay) were incubated in phosphorylation
buffer (50 mmol/l HEPES [pH 7.5], 150 mmol/l NaCl, 10 mmol/l MnCl2, 10
mmol/l MgCl2, 10 mol/l Na3VO4, and 0.02% Triton X-100) containing 60 mol/l
ATP in a final volume of 25 l. After stimulation by EGF (10 nmol/l at 37°C for
15 min), the reaction was stopped by adding 15 l of 4  sample-reducing
buffer (19) and heating at 90°C for 5 min. Tyrosine phosphorylation and EGFR
content were analyzed by SDS-PAGE and Western blot as described above.
Alternatively, autophosphorylation of EGFR was studied by adding 5 Ci
of [-33P]ATP (3,000 Ci/mmol) to the phosphorylation buffer. The reaction was
stopped by spotting an aliquot of the mixture on phosphocellulose mem-
branes, and its radioactivity was subsequently counted (23). Tyrosine kinase
activity was evaluated in the same conditions by phosphorylation of poly-Glu-
Tyr (23).
Derivatization of the EGFR free amino groups. After preincubation of
ECV304 cells with 5 mmol/l GO or MGO for 5 h, EGFR was immunoprecipi-
tated, and the free amino group content was evaluated by using the amine-
reactive probe [3H]SP (23). Free amino groups were derivatized with 10 Ci of
[3H]SP in borate buffer 0.5 mol/l, pH 8.5, at 4°C for 15 min. The immunopre-
cipitates were washed three times in borate buffer and boiled in 4 
sample-reducing buffer. EGFR were then resolved by SDS-PAGE, the 170-kDa
bands were recovered, and the radioactivity was counted by liquid scintilla-
tion (23).
Determination of protein tyrosine phosphatase activity. Protein tyrosine
phosphatase (PTPase) activity was determined according to Buscail et al.
(24). Briefly, PTPase activity of homogenates of cells (preincubated with GO
and then stimulated by EGF) was evaluated by [33P]poly-Glu-Tyr dephosphor-
ylation under the previously used conditions (25). Protein concentrations
were measured by the bicinchoninic acid method (23).
RESULTS
GO and MGO inhibit EGFR tyrosine phosphorylation
and subsequent cell signaling. In ECV304 preincubated
with GO or MGO for increasing periods of time, EGF-
induced phosphorylation of cell proteins was progres-
sively inhibited in a time-dependent manner, and the
inhibitory effect of GO was obvious after 2-h preincubation
(or 30 min in the case of MGO) (Fig. 1A and B). As
expected, the 170-kDa band phosphorylated after EGF
stimulation was identified as EGFR by immunoprecipita-
tion followed by Western blot, as shown in Fig. 2.
The dose-response study showed that under the condi-
tions used, the inhibitory effect of the EGF-induced EGFR
autophosphorylation began at 0.5 mmol/l GO or MGO and
was higher at 5 mmol/l (Fig. 1C). This inhibitory effect was
not restricted to the ECV304 cell line but was observed on
all the cell lines used in this study, namely A-431 cancer
cells, B82K fibroblasts, and rabbit vascular smooth mus-
cle cells.
It may be noted that at the concentrations used here and
over the course of the experiments (7 h), we observed no
loss of cell number and of cell viability (as assessed by
MTT test and trypan blue exclusion test). When cells were
incubated with GO or MGO for longer incubation times, a
moderate toxic effect was observed after 24-h incubation
with 5 mmol/l GO or MGO but not with 0.5 mmol/l GO or
MGO (data not shown). This suggests that the inhibition of
EGF-induced EGFR autophosphorylation resulting from
the 6-h preincubation with 0.5 or 5 mmol/l GO or MGO
cannot be attributed to cell loss or a toxic effect at that
time.
To evaluate whether inhibition by GO and MGO of the
EGF-induced EGFR autophosphorylation was associated
with alteration of the downstream signaling, we examined
some of the mediators of this signaling pathway. As shown
by coimmunoprecipitation experiments (Fig. 2A), preincu-
bation of cells with GO inhibited the recruitment of PLC1
to EGF-activated EGFR. In addition, the EGF-induced
activation of the serine-threonine kinases ERK1/2, other
downstream effectors of growth factor signaling pathways,
were also inhibited by GO and MGO (Fig. 2B and C).
Interestingly, with MGO, ERK1/2 inactivation was more
rapid than that of EGFR, thus suggesting that an additional
mechanism may be involved in the MGO-induced inactiva-
tion of ERKs, in agreement with the recent report of
Akhand et al. (26).
The inhibition elicited by GO and MGO on the response
of these effectors (PLC1 and ERK1/2) is consistent
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with the inhibitory effect of these aldehydes on the EGF-
induced EGFR activation.
Mechanisms involved in GO- or MGO-induced EGFR
inhibition
The inhibitory effect did not result from EGF modi-
fication by GO and MGO. The inhibitory effect was
probably not due to a direct effect of GO and MGO on EGF
because the inhibitory effect was dependent on the time of
contact of GO/MGO with cells (in the absence of EGF) and
was independent of the time of contact of GO/MGO with
EGF (15-min incubation) (Fig. 1A and B) and because the
same inhibitory effect was observed in experiments with
continuous presence of GO/MGO (i.e., when EGF was
added to the medium containing GO/MGO at the end of
preincubation) and in pulse-chase experiments (i.e., when
EGF was added after washing out GO/MGO at the end of
the 6-h preincubation, just before addition of EGF) (data
not shown).
The inhibitory effect did not result from a loss of
EGFR protein induced by GO and MGO. The inhibi-
tory effect did not result from a loss of EGFR protein
because when the same amount of cell protein extract was
used for Western blots revealed by anti-EGFR, a similar
level of EGFR protein was detected (Figs. 1 and 2) and
because when the same amount of immunoprecipitated
EGFR protein was used for Western blots revealed by
anti-phosphotyrosine and anti-EGFR, the EGFR tyrosine
phosphorylation (i.e., reactivity with anti-phosphotyro-
sine) was reduced, whereas the amount of EGFR protein
(i.e., reactivity with anti-EGFR) remained unchanged (Figs. 1
and 2). This strongly suggests that moderate concentra-
tions (0.5 mmol/l) of GO and MGO inhibit the EGFR kinase
activity but do not alter the level of the EGFR protein.
However, it may be noted that high concentrations of
GO induced the formation of anti-EGFR immunoreactive
high-molecular-weight bands (arrow of Fig. 1D), suggest-
ing the formation of high-molecular-weight complexes
containing cross-linked and/or aggregated EGFR.
GO and MGO inhibit PTPase activity. Theoretically,
the reduced EGF-induced EGFR autophosphorylation elic-
ited by GO or MGO may result either from a defect of
phosphorylation or an excess of dephosphorylation. Since
recently reported data show that GO and MGO upregu-
lated the activity of the protein phosphatase MKP-1 (26),
we examined whether the aldehydes may also activate
PTPases and the rate of EGFR dephosphorylation. Deter-
mination of overall cellular PTPase activity showed that
under the conditions used, pretreatment of cells with GO
(and MGO, data not shown) induced a severe inhibition of
PTPase activity under both basal and EGF-stimulated
conditions (Fig. 3A). Conversely, pulse-chase experiments,
in which cells were preincubated or not with MGO, then
stimulated with EGF, and then chased for variable time,
showed that in MGO-treated cells, EGFR phosphorylation
FIG. 1. EGFR tyrosine phosphorylation is inhibited by GO and MGO. Cells were starved for 16 h in RPMI-1640 containing 0.5% FCS and then
incubated with GO or MGO at the indicated times and concentrations. Cell lysates were analyzed by Western blotting (SDS-PAGE on 7.5%
polyacrylamide gels) and probed with anti-phosphotyrosine (anti-PY) or anti-EGFR. Data shown are representative of four experiments. A and
B: Time course of inhibition of EGF-induced EGFR autophosphorylation on ECV304 cells, either control or incubated with 5 mmol/l GO (A) or
MGO (B) for the indicated time and stimulated by EGF (10 nmol/l for 15 min). C and D: Dose response of EGFR tyrosine phosphorylation in
ECV304 cells (C) and B82K fibroblasts (D) incubated (or not) for 6 h with GO at the indicated concentrations and stimulated by EGF (10 nmol/l
for 15 min). The arrow indicates the presence of anti-EGFR reactive high-molecular-weight aggregates.
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was lower but was maintained for a longer time (Fig. 3B).
This MGO-induced delay of EGFR dephosphorylation was
consistent with the inhibition of PTPase activity.
Therefore, inhibition by GO/MGO of the EGF-induced
EGFR autophosphorylation does not result from an accel-
erated dephosphorylation due to PTPase activation. This
led us to investigate whether GO or MGO directly inhibit
EGFR kinase.
GO and MGO directly inhibit EGFR phosphorylation
and tyrosine kinase activation. To investigate whether
GO and MGO act directly on EGFR, we evaluated in vitro
the EGFR kinase activity of EGFR immunopurified from
ECV304 cells preincubated with GO and MGO. As shown
in Fig. 4A and B, preincubation with MGO and GO inhib-
ited the tyrosine kinase activity of EGFR (evaluated by
EGFR autophosphorylation and phosphorylation of poly-
Glu-Tyr). MGO was more active than GO.
All in vitro experiments gave similar results. In vitro
preincubation of EGFR-rich membrane fractions from
A431 cells with GO inhibited the in vitro EGF-induced
EGFR autophosphorylation (Fig. 4C). Furthermore, EGFR
tyrosine kinase activity was also decreased by GO and
MGO in this system (data not shown).
All these data suggest that both GO and MGO (the latter
FIG. 2. GO and MGO alter EGFR downstream signaling. A: Inhibition of EGF-induced recruitment of PLC1 on EGFR. ECV304 cells were
incubated with GO (5 mmol/l for 6 h) and then stimulated by EGF (10 nmol/l for 15 min). The cells were lysed in solubilization buffer (which allows
coimmunoprecipitation of SH2-proteins bound to EGFR) and (1.5 mg cell protein) immunoprecipitated with anti-EGFR antibody overnight at 4°C.
Anti-EGFR immunoprecipitates were recovered on protein G-Sepharose (1 h at 4°C), washed, eluted, and analyzed by SDS-PAGE. The spots were
revealed by immunoblotting with anti-phosphotyrosine, anti-EGFR, and anti-PLC1. Data shown is representative of three experiments. B and
C: Time course of inhibition of ERK activation subsequent to EGF stimulation. ECV304 cells, preincubated at variable periods of time with 5
mmol/l GO (B) or MGO (C), were stimulated with EGF (10 nmol/l for 15 min), and ERK activation was investigated by Western blot using
antibodies against activated ERK (anti-phosphorylated ERK1/ERK2 [anti-pERK]) and total ERK (anti-ERK1/ERK2 [anti-ERK]). These data are
representative of three separate experiments.
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being more efficient) directly inhibit EGFR autophosphor-
ylation and tyrosine kinase activity. The in vitro inhibition
of EGFR and the formation of high-molecular-weight
aggregates of EGFR (detected by anti-EGFR antibodies)
(Fig. 4C, lower panel) led us to hypothesize that GO and
MGO may react with EGFR.
Derivatization of EGFR and cell proteins by GO and
MGO: prevention by aminoguanidine
Formation of GO- and MGO-EGFR adducts. GO and
MGO are highly reactive compounds, capable of reacting
with free amino groups of cell proteins and forming AGEs
(8). To evaluate whether GO and MGO derivatized basic
amino acids of EGFR, we titrated the free reactive amino
group content using the amine-reactive probe [3H]SP (23).
Both GO and MGO induced a significant reduction in the
free amino group content of EGFR (Fig. 5A). These data
suggest that preincubation of cells with GO or MGO
induced the formation of GO- and MGO-EGFR adducts.
CML is an AGE product that arises from the reaction of GO
with lysine. The presence of the GO-derived AGE was
FIG. 3. Altered PTPase activity and EGFR dephosphorylation in cells incubated with GO and MGO. A: PTPase activity was evaluated in ECV304
cells preincubated (or not) with GO (0.5 and 5 mmol/l) for 5 h. PTPase activities were measured as described in RESEARCH DESIGN AND METHODS by
dephosphorylation of [33P]poly-Glu-Tyr. Data are expressed as percent of PTPase activation versus the basal control. Results are the means  SD
from four separate experiments. **P < 0.001 vs. unstimulated cells (control) (ANOVA). B: Inhibition of EGFR dephosphorylation by MGO. EGF
(10 nmol/l) was added to ECV304 cells on ice. After binding on ice for 15 min, the cells were washed, chased at 37°C in EGF-free medium for the
time periods indicated, and lysed in solubilizing buffer. After equilibration of protein concentration, cell lysates were analyzed by Western blot
with an anti-phosphotyrosine antibody and developed by ECL as described in the text. These data are representative of three separate
experiments.
FIG. 4. In vitro inhibition of EGFR activation induced by GO and MGO. A: EGFR autophosphorylation was determined on EGFR immunopurified
from unstimulated ECV304 (previously incubated in situ without or with 0.5 and 5 mmol/l GO and MGO for 5 h) and incubated in vitro without
(control) or with 1 nmol/l EGF for 15 min. The assay was performed in phosphorylation buffer containing 5 Ci/assay of [-33P]ATP, as described
in RESEARCH DESIGN AND METHODS. After spotting on phosphocellulose membranes, the radioactivity was counted. Data are expressed as percent of
the unstimulated control. B: EGFR tyrosine kinase activity was evaluated using the same protocol but in the presence of the poly-Glu-Tyr
substrate. Results are the means  SD from four separate experiments. *P < 0.02, **P < 0.001 vs. unstimulated cells (control) (ANOVA). C:
Western blot experiments of EGFR in membranes prepared from A-431 cells and preincubated in phosphorylation buffer with or without 5 mmol/l
GO (30 min), then stimulated with 1 nmol/l EGF (15 min), and then blotted with anti-phosphotyrosine and anti-EGFR antibodies. The arrow
indicates the presence of anti-EGFR reactive high-molecular-weight aggregates. Data are representative of three separate experiments.
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confirmed by Western blotting of proteins from cells
preincubated with GO (Fig. 5B) by anti-CML antibody.
Aminoguanidine prevents the formation of GO- and
MGO-EGFR and protein adducts. Since aminoguani-
dine is able to prevent protein derivatization by dicarbonyl
compounds (27,28), we investigated whether aminoguani-
dine can protect EGFR function against GO and MGO. As
shown in Fig. 6, preincubation of cells with aminoguani-
dine before treatment by GO and MGO resulted in the
protection of EGF-induced activation of EGFR and ERK1/2.
This protection was almost complete against 5 mmol/l GO
and partial against 5 mmol/l MGO.
Taken together, these data strongly suggest that the
inhibitory action of GO and MGO on EGFR signaling was
related to EGFR modification by these two AGE precur-
sors and that this inhibitory effect can be prevented by
aminoguanidine.
DISCUSSION
The reported data show, for the first time, that activation
of the EGFR signaling pathway is inhibited by the dicar-
bonyl compounds GO and MGO in a time- and dose-
dependent manner. The novelty of our results lies in the
demonstration that EGFR is a target of GO and MGO, that
GO and MGO induce the formation of GO/MGO-EGFR
adducts and abrogate EGF-induced EGFR autophosphor-
ylation and the activation of two of the major EGFR
downstream signaling pathways, namely ERK and PLC,
and that the formation of GO/MGO-EGFR (and GO/MGO–
protein adducts) and subsequent inhibition of EGFR sig-
naling can be prevented by aminoguanidine.
This aldehyde-induced inhibition is a novel mechanism
of negative regulation of EGFR signaling. Because recep-
tor protein tyrosine kinase signaling systems allow the cell
to integrate a multitude of signals from its environment,
the impairment of these basic mechanisms by reactive
aldehydes could have profound effects on cellular physi-
ology, including motility and cell fate determination such
as differentiation, proliferation, and apoptosis. This con-
cept agrees with the recently described role of MGO as a
putative signal molecule in cell death (29).
Our results establish a clear relationship between mo-
lecular modifications (i.e., GO/MGO-EGFR adduct forma-
tion) and functional alterations (i.e., impairment of the
EGFR signaling pathway). Under the conditions used, GO
and MGO are able to derivatize EGFR, as assessed by a
loss in [3H]SP-reactive amino groups content of EGFR and
by AGE-protein formation, as visualized by anti-CML anti-
body. This is consistent with the known reactivity of
GO/MGO with amino groups of proteins (5). Reaction of
GO/MGO with EGFR is also evidenced by the formation of
high-molecular-weight aggregates reacting with anti-EGFR
antibody. This is in agreement with the well-known asso-
ciation between AGE adducts and cross-linking of proteins
(30).
Derivatization of EGFR by dicarbonyls and inhibition of
EGFR kinase activity are concomitant events that are
probably causally related, as suggested by in vitro exper-
iments on purified EGFR and by the protective effect of
aminoguanidine, a known dicarbonyl scavenger (27,28).
Dicarbonyls may induce nonenzymatic modifications of
various amino acids (Cys, Lys, or Arg) that are generally
present in the putative active site of the receptor tyrosine
FIG. 5. Inhibitory effect of GO and MGO is related to AGE formation in
EGFR. A: Derivatization of EGFR free amino groups by GO and MGO.
ECV304 cells preincubated with GO or MGO (5 mmol/l for 5 h) were
treated without (control) or with EGF (1 nmol/l for 15 min), and EGFR
was immunoprecipitated as described above. Free amino groups of
EGFR were labeled with [3H]SP, as indicated in RESEARCH DESIGN AND
METHODS. EGFR was resolved by SDS-PAGE, and the radioactivity of the
170-kDa bands was counted. Results are the means  SD from three
separate experiments. *P < 0.02 vs. unstimulated cells (control)
(ANOVA). B: Detection of CML adducts by anti-CML antibodies in
proteins from ECV304 cells preincubated with GO for 5 h at the
indicated concentrations. Data are representative of four separate
experiments.
FIG. 6. Aminoguanidine prevents GO- and MGO-induced inhibition of
EGF signaling in ECV304 cells. Cells were preincubated with or
without aminoguanidine (5 mmol/l) for 8 h, exposed to GO or MGO (5
mmol/l for 5 h, as indicated), and stimulated with EGF. Analysis of
EGFR phosphorylation and ERK phosphorylation was performed as
described in RESEARCH DESIGN AND METHODS. Data are representative of
four separate experiments.
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kinase family (31). Some other hypothetical mechanisms
potentially involved in dicarbonyl-induced EGFR inhibi-
tion have been excluded: 1) GO and MGO were not
cytotoxic to cultured cells under the conditions used in the
experiment; 2) the loss of EGFR activity was not associ-
ated with a loss of EGFR protein but rather resulted from
a reduced specific activity of the EGFR kinase; 3) the
GO/MGO–induced inhibition of EGFR phosphorylation
does not result from activation of PTPases (involved in
EGFR dephosphorylation) because, under our experimen-
tal conditions, GO/MGO strongly inhibited PTPases, in
agreement with a previous report (32); and 4) GO/MGO-
induced EGFR inhibition is not prevented by antioxidants
such as -tocopherol and N-acetyl-cysteine (data not
shown).
All these data strongly support the hypothesis that
derivatization of EGFR by GO/MGO induces inhibition of
EGFR kinase, thereby inhibiting EGFR autophosphoryla-
tion and downstream signaling pathway.
The broad capacity of dicarbonyls to induce protein
derivatization suggests that GO/MGO may alter the func-
tion of other signaling proteins. This hypothesis was
confirmed by the ability of GO/MGO to inhibit the activity
of another tyrosine kinase receptor, the PDGFR in smooth
muscle cells (Fig. 7). In the same way, the data on
GO/MGO–induced dephosphorylation of ERKs (which are
inhibited more rapidly than EGFR) suggest that other
signaling proteins are targets for dicarbonyls. In this case,
GO/MGO have been shown to activate MKP-1, a phospha-
tase involved in ERK dephosphorylation (26).
The reported GO/MGO–induced inhibition of EGFR and
PDGFR signaling pathways observed in cultured cells is
consistent with the growth factor resistance (including
EGF) induced by high glucose concentrations in cultured
fibroblasts (33).
The concentrations of GO/MGO used here are similar to
those generally used to evaluate the biological effects of
these dicarbonyls (10,11,26,34) and are consistent with
those (high micromolar range) found in living systems
(35). Moreover, these concentrations are close to those
used in vitro to generate AGE content in a physiological
range (8,36).
The GO/MGO–induced defects in cell signaling may be
relevant to various steps of the pathophysiology of aging
and diseases, with increased levels of dicarbonyls or
AGEs, such as diabetes, uremia, and atherosclerosis
(6,37). In diabetes, glycation of proteins is associated with
increased generation of GO and MGO (3,38) and altered
EGFR signaling (14–17). Concurrent to the AGE/RAGE–
induced cell activation (39), this GO/MGO–induced impair-
ment in response of growth factors and the subsequent
trophic deprivation may be implicated in the pathophysi-
ology of chronic diabetic complications, such as microvas-
cular disease (including neuropathy, nephropathy, and
retinopathy) and macrovascular disease (and associated
accelerated atherosclerosis), impaired wound healing
(33,40), and placenta dysfunction (16).
Finally, the protective effect of the dicarbonyl scavenger
aminoguanidine, which prevents GO/MGO–induced EGFR
signaling impairment, is also consistent with the effective-
ness of aminoguanidine to slow the progression of a wide
range of diabetic complications (41,42).
In conclusion, this study of the dicarbonyl-induced
defect of growth factor response adds a new potential
mechanism to the complex pathophysiology of chronic
diabetic complications and other diseases associated with
increased production of reactive aldehydes.
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